Express Pharma

Thermo Fisher Scientific Expands SARS-CoV-2 Testing Portfolio in India with Point-of-Care Testing Platform.

0 339

The Accula System is an innovative platform that will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care

Mumbai, India, June 15, 2021Thermo Fisher Scientific today announced a introduction of the new and innovative SARS-CoV-2 Test that delivers gold-standard reverse transcription polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format. 

The Accula SARS-CoV-2 Test has received Emergency Use Authorization (EUA) from the United States (U.S.) Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.